## Contents

<table>
<thead>
<tr>
<th>Volume 93</th>
<th>Issue 7</th>
<th>JNNP July 2022</th>
</tr>
</thead>
</table>

### Editorial commentary

**685** VEXAS syndrome extends the neurological complications of haemopathies  
*P Coca*

### Cerebrovascular disease

**686** Antithrombotic therapy in the postacute phase of cerebral artery dissection: the Italian Project on Stroke in Young Adults Cervical Artery Dissection  

**693** Isotopic cerebral amyloid angiopathy: an emerging clinical phenomenon  

### Movement disorders

**707** Combining biomarkers for prognostic modelling of Parkinson’s disease  
*N Vajkaranam, M Lawton, A J Heslegrave, T Guo, M Tan, E Jabbari, R Real, J Woodside, K Grosset, V Chellam, D Athauda, C Géres, R A Barker, J Hardy, N Wood, H Holden, N Williams, Y Ben-Shlomo, H Zetterberg, D G Grosset, T Foltynie, H R Morris, ProfNCDN Clinical consortium*

### Multiple sclerosis

**716** Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis  
*M Magni, N Koch-Henriksen*

**723** Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia  
*S Simpson-Yap, R Atavas, L Blizzard, I van der Mei, B V Taylor*

**732** Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis  
*M Comabella, J Sastre-Garriga, P Carbonell-Munabert, N Fossolo, C Tor, S Malhotra, D Pareto, F X Aymerich, J Hoc, A Rentia, M Tintore, X Montalban*

**741** Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study  

### Neuro-inflammation

**753** MR T2-relaxation time as an indirect measure of brain water content and disease activity in NMOSD  
*L Cacciaguerre, E Pagani, M Radaelli, S Mesaros, V Martinelli, J Ivanovic, J Dulovic, F Filippi, M A Roca*

---

**Disclaimer:** The Editor of JNP has been granted editorial freedom and JNP is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. JNP is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by JNP does not imply endorsement. BMJ Publishing Group Limited shall not be liable for any loss, injury or damage however arising from JNP except for liability which cannot be legally excluded.

**Copyright:** © 2022 BMJ Publishing Group Ltd. All rights reserved; no part of this publication may be reproduced in any form without permission. JNP is published by BMJ Publishing Group Ltd, 7th Floor, Eustor Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper from sustainable forests. Journal of Neurology Neurosurgery & Psychiatry ISSN 0022-3050 (DPS) 2150 is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent World Container Inc. 150-15, 183rd Street, Jamaica, NY 11433, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Journal of Neurology Neurosurgery & Psychiatry, World Container Inc. 150-15, 183rd Street, Jamaica, NY 11433, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London Air Business Ltd is acting as our mailing agent.

---

**Movement disorders**

**707** Combining biomarkers for prognostic modelling of Parkinson’s disease  
*N Vajkaranam, M Lawton, A J Heslegrave, T Guo, M Tan, E Jabbari, R Real, J Woodside, K Grosset, V Chellam, D Athauda, C Géres, R A Barker, J Hardy, N Wood, H Holden, N Williams, Y Ben-Shlomo, H Zetterberg, D G Grosset, T Foltynie, H R Morris, ProfNCDN Clinical consortium*
Neurodegeneration
761 Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis

772 APOE ε4 dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction
Y Uchida, H Kan, K Sakurai, Y Horimoto, E Hayashi, A Iida, N Okamura, K Oishi, N Matsumura

Neuropsychiatry
785 Discrepancy between disability and reported well-being after traumatic brain injury
I R A Retel Helmrich, D van Klaveren, N Andelic, H Lingoma, A Maas, D Monen, S Polinder, C Roe, E W Steyerberg, E Van Veen, J Wilson, The CENTER-TBI participants and investigators

PostScript
797 Letter